All patients (n=357) | Gold standard (n=82) | FN Patients: neutropenia, primary position (n=54) | FN Patients: neutropenia, any position (n=71) | FN Patients: Neutropenia + Fever,Any Position (n=28) | FN Patients: neutropenia or fever, any position (n=78) | FN Patients: neutropenia, fever, or infection, any position (n=201) | |
---|---|---|---|---|---|---|---|
Patient | |||||||
Age (years), mean±SD | 64.2±13.0 | 62.1±13.8 | 63.3±15.1 | 62.6±14.8 | 61.3±16.3 | 63.0±14.5 | 65.5±12.3 |
Male, % | 56.0 | 51.2 | 42.6 | 40.9 | 39.3 | 44.9 | 56.2 |
Body Mass Index (kg/m2), mean±SD | 27.3±5.9 | 27.8±4.5 | 27.8±4.7 | 28.1±4.7 | 28.1±5.7 | 28.2±5.1 | 27.3±5.2 |
N | 332 | 77 | 51 | 67 | 28 | 74 | 192 |
Absolute Neutrophil Count (cells/L), mean±SD | 4.4±5.6 | 0.2±0.3 | 0.3±0.9 | 0.9±3.3 | 0.2±0.2 | 1.1±3.5 | 4.4±6.3 |
N | 357 | 82 | 54 | 71 | 28 | 78 | 201 |
Cancer | |||||||
Type % | |||||||
Bone, Connective Tissue, Skin, Breast | |||||||
Female Breast | 9.8 | 19.5 | 18.5 | 18.3 | 28.6 | 17.9 | 11.9 |
Other | 2.8 | 1.2 | 1.9 | 2.8 | 3.6 | 2.6 | 2.5 |
Respiratory and Intrathoracic Organs | |||||||
Trachea, Bronchus, Lung | 19.3 | 17.1 | 9.3 | 9.9 | 14.3 | 10.3 | 20.9 |
Other | 1.4 | 2.4 | 5.6 | 4.2 | 3.6 | 3.8 | 2.0 |
Digestive Organs and Peritoneum | |||||||
Colon/Rectum | 10.9 | 9.8 | 5.6 | 5.6 | 7.1 | 5.1 | 9.5 |
Pancreas | 7.8 | 1.2 | 1.9 | 2.8 | 0.0 | 5.1 | 7.0 |
Esophagus | 2.5 | 2.4 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 |
Other | 3.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.0 |
Non-Hodgkin's Lymphoma | 11.2 | 20.7 | 25.9 | 23.9 | 28.6 | 24.4 | 14.9 |
Genitourinary Organs | |||||||
Bladder | 4.2 | 3.7 | 3.7 | 4.2 | 0.0 | 3.8 | 5.0 |
Ovarian | 3.6 | 1.2 | 5.6 | 4.2 | 0.0 | 3.8 | 3.0 |
Prostate | 2.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.0 |
Uterus | 1.7 | 0.0 | 0.0 | 1.4 | 0.0 | 1.3 | 0.5 |
Other | 2.8 | 1.2 | 1.9 | 1.4 | 0.0 | 1.3 | 2.0 |
Lip, Oral Cavity, and Pharnyx | 2.0 | 1.2 | 0.0 | 0.0 | 0.0 | 0.0 | 1.5 |
Blood Cancers | 6.7 | 13.4 | 13.0 | 14.1 | 14.3 | 14.1 | 8.0 |
Hodgkin’s Lymphoma | 1.7 | 1.2 | 1.9 | 1.4 | 0.0 | 1.3 | 0.5 |
Other | 5.6 | 3.7 | 5.6 | 5.6 | 0.0 | 5.1 | 5.0 |
Presence of Metastases, % | 35.0 | 24.4 | 22.2 | 21.1 | 17.9 | 20.5 | 26.4 |
Chemotherapy | |||||||
No. of Myelosuppressive Drugs in Cycle 1, % | |||||||
1 | 32.2 | 20.6 | 26.1 | 27.4 | 38.1 | 29.4 | 29.2 |
2 | 47.2 | 50.7 | 45.7 | 46.8 | 38.1 | 44.1 | 49.7 |
≥3 | 20.6 | 28.8 | 28.3 | 25.8 | 23.8 | 26.5 | 21.1 |
Year of Initiation, % | |||||||
2004-2005 | 41.7 | 37.8 | 42.6 | 42.3 | 14.3 | 39.7 | 37.3 |
2006-2007 | 28.3 | 28.1 | 22.2 | 23.9 | 32.1 | 23.1 | 31.4 |
2008-2010 | 30.0 | 34.2 | 35.2 | 33.8 | 53.6 | 37.2 | 31.3 |